The Impact of Linezolid and Vancomycin Treatment on Local Signs and Symptoms of Inflammation Among Pediatric Patients With Complicated Skin and Skin Structure Infections
Restricted accessResearch articleFirst published online November, 2011
The Impact of Linezolid and Vancomycin Treatment on Local Signs and Symptoms of Inflammation Among Pediatric Patients With Complicated Skin and Skin Structure Infections
TsengCWKymePLowJ. Staphylococcus aureus Panton-Valentine leukocidin contributes to inflammation and muscle tissue injury. PLoS One. 2009;4:e6387.
2.
LominskiIArbuthnottJP. Some characteristics of Staphylococcus alpha haemolysin. J Pathol Bacteriol. 1962;83:515-520.
3.
YanagiharaKKiharaRArakiN. Efficacy of linezolid against Panton-Valentine leukocidin (PVL)-positive meticillin-resistant Staphylococcus aureus (MRSA) in a mouse model of haematogenous pulmonary infection. Int J Antimicrob Agents. 2009;34:477-481.
4.
StevensDLWallaceRJHamiltonSMBryantAE. Successful treatment of staphylococcal toxic shock syndrome with linezolid: a case report and in vitro evaluation of the production of toxic shock syndrome toxin type 1 in the presence of antibiotics. Clin Infect Dis. 2006;42:729-730.
5.
YogevRPattersonLEKaplanSL. Linezolid for the treatment of complicated skin and skin structure infections in children. Pediatr Infect Dis J. 2003;22:S172-S177.
6.
Centers for Disease Control and Prevention (CDC). Methicillin-resistant Staphylococcus aureus infections among competitive sports participants-Colorado, Indiana, Pennsylvania, and Los Angeles County, 2000-2003. MMWR Morb Mortal Wkly Rep. 2003;52:793-795.
7.
JerniganJATitusMGGroschelDH. Effectiveness of contact isolation during a hospital outbreak of methicillin-resistant Staphylococcus aureus. Am J Epidemiol. 1996;143:496-504.
8.
CreamerEDorrianSDolanA. When are the hands of heathcare workers positive for methicillin-resistant Staphylococcus aureus?J Hosp Infect. 2010;75:107-111.
9.
GeeTEllisRMarshallG. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob Agents Chemother. 2001;45:1843-1846.
